A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old.
Patients with a morphologically proven diagnosis AML and both the two following criteria:
- Age > 50 years and £ 70 years.
- Not previously treated for their disease.
Randomization will be centralized by phone :
Arm A chemotherapy with daunorubicin and Aracytine or Arm B Daunorubicin and Aracytine and
Mylotarg.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Event Free Survival (EFS)
Relapse or death measured from randomization
No
Castaigne Sylvie, Professor
Principal Investigator
Central Hospital, Versailles
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
ALFA 0701
NCT00927498
December 2007
January 2010
Name | Location |
---|